ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: 2440 • ACR Convergence 2025

    Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study

    Anca Askanase1, Bruno Flamion2, Ouali Berkani2 and Cecile Dubois2, 1Columbia University Medical Center, New York, NY, 2Viatris Innovation, Allschwil, Switzerland

    Background/Purpose: Cenerimod is a selective S1P1 receptor modulator that has the potential to reduce the abnormal immune response seen in Systemic lupus erythematosus (SLE) thereby…
  • Abstract Number: 2288 • ACR Convergence 2025

    Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial

    Yuan Xue, Bo Wei, Xiaojing Huang and Rui Ding, Zhongshan Hospital Xiamen University, Xiamen, China (People's Republic)

    Background/Purpose: Ivarmacitinib (SHR0302), a selective Janus kinase 1 inhibitor, has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA). This post-hoc study aimed to evaluate…
  • Abstract Number: 2012 • ACR Convergence 2025

    A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China

    ullrich schwertschlag1, yan yang2, Jingfei li3, Roy Wu4, adam jin2 and William Shi5, 1Atom Therapeutics, PALO ALTO, CA, 2Atom Therapeutics, Suzhou, China (People's Republic), 3Atom Therapeutics, Suzhou, Jiangsu, China (People's Republic), 4Atom Bioscience, San Francisco, CA, 5Atom Therapeutics, Newark, CA

    Background/Purpose: ABP-671 is a novel, selective and potent URAT1 inhibitor in development for the treatment of elevated serum uric acid (sUA) levels and gout.Methods: Subjects…
  • Abstract Number: 1545 • ACR Convergence 2025

    Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study

    Susan Manzi1, Ian Bruce2, Eric Morand3, Richard Furie4, Yoshiya Tanaka5, Patricia Puzio6, Emon Khan7, Jenny Wissmar8, Michael Song9 and Catharina Lindholm10, 1Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, 2Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, 3Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, 4Division of Rheumatology, Northwell Health, Great Neck, NY, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, MD, 7BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom, 8BioPharmaceuticals R&D, Late-Stage Development, Respiratory & Immunology, AstraZeneca, Gothenburg, Sweden, 9BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Boston, MA, 10BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Intravenous (IV) anifrolumab (300 mg, every 4 weeks [Q4W]) is an approved biologic add-on therapy for moderate to severe SLE;1 a subcutaneous (SC) formulation…
  • Abstract Number: 1441 • ACR Convergence 2025

    Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study

    Hongbin Li1 and Huilin Li2, 1Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Nei Mongol, China (People's Republic), 2Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic)

    Background/Purpose: Vunakizumab, a humanized anti-interleukin-17A monoclonal antibody, has shown significant efficacy and favorable safety in patients with active ankylosing spondylitis (AS), leading to its approval…
  • Abstract Number: 0720 • ACR Convergence 2025

    Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials

    Manuel Carpio Tumba1, Aida Mohamadi2, Diana Louden3, Victor Pimentel-Quiroz4, Michael Putman5, Didem Saygin6, Raisa Lomanto Silva7 and Sebastian E Sattui8, 1University of Pittsburgh, Pittsburgh, PA, 2Tehran University of Medical Sciences, Tehran, Iran, 3University of Washington, Seattle, WA, 4Universidad Científica del Sur, San Isidro, Peru, 5The Medical College of Wisconsin, Milwaukee, WI, 6Rush University Medical Center, Chicago, IL, 7Massachusetts General Hospital, Boston, MA, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Randomized controlled trials (RCTs) generate unbiased efficacy estimates and are required for regulatory approval. Understanding the degree to which they include racial, ethnic, sex,…
  • Abstract Number: 0572 • ACR Convergence 2025

    Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort

    Jean-Guillaume Letarouilly1, Elnaz Saeedi2, Raphaël Hurtubise3, Lija James4, Nicola Gullick5, Deepak Jadon6, William Tillett7, Yvonne Sinomati4, Laura Tucker4, Nadia Mian8, Sophia Massa3 and Laura Coates9, 1Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, LILLE, Nord-Pas-de-Calais, France, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, United Kingdom, 4Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK, Oxford, United Kingdom, 5Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, 6Department of Medicine, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, 7Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, 8BM BS, MMedSc,, Oxford, United Kingdom, 9Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom

    Background/Purpose: A treat-to-target (T2T) strategy in psoriatic arthritis (PsA) is supported by International PsA recommendations but not widely practiced in clinic. The aim of the…
  • Abstract Number: 0777 • ACR Convergence 2025

    Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

    Kevin Byram1, Herman Mann2, Danielle Hammond3, Sinisa Savic4, Yohei Kirino5, Carmelo Gurnari6, Mael Heiblig7, Thibault Comont8, Arsène Mekinian9, Mrinal Patnaik10, Lachelle D. Weeks11, Gary Ho12, Onima Chowdhury13, Adam Al-Hakim14, Scott Goldberg15, Marcela ferrada16, Sophie georgin-Lavialle17, Peter Grayson18, Emma Groarke19, Bhavisha Patel20, Megan Sullivan21, Sarah A. Buckley22, Bryan G. harder22, Sandra Goble22, Matthew Koster10 and David Beck23, 1Vanderbilt University Medical Center, Nashville, TN, 2Institute of Rheumatology, Praha 2, Czech Republic, 3The University of Texas MD Anderson Cancer Center, Houston, TX, 4University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 5Yokohama City University Graduate School of Medicine, Yokohama, Japan, 6Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, 7Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, 8Centre Hospitalier Universitaire Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, 9Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i3), Saint-Antoine University Hospital, 75012 Paris, France, Paris, France, 10Mayo Clinic, Rochester, MN, 11Dana Farber Cancer Institute, Boston, MA, 12New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, 13Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, 14University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine,, Leeds, United Kingdom, 15New York University Grossman School of Medicine, Brooklyn, NY, 16University of Maryland, Bethesda, MD, 17Sorbonne university, Tenon hospital, DMU3ID, CEREMAIA, ERN RITA, Paris, France, 18National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, 19National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, 20National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, 21Mayo Clinic Arizona, Scottsdale, AZ, 22Sobi Inc., Waltham, MA, 23Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY

    Background/Purpose: VEXAS syndrome is a recently described severe disease characterized by a complex overlap of inflammatory and hematologic features. Due to the severity and refractory…
  • Abstract Number: 0401 • ACR Convergence 2025

    Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry

    Daniel Lovell1, Nicolino Ruperto2, Jennifer Huggins3, Ekaterina Alexeeva4, Colleen Correll5, John Bohnsack6, Stacey Tarvin7, Gabriele Simonini8, Thomas Griffin9, Andrew Zeft10, Gerd Horneff11, Pierre Quartier12, Iionka Orban13, Heather Walters14, Valda Stanevica15, Julisa Patel16, Adam M Huber17, Margalit Rosenkranz18, Daniel Kingsbury19, Rosie Scuccimarri20, Gabriel Vega Cornejo21, Joost Swart22, Robert Carroll23, Hermine Brunner1, Tina Sherrard24, Chiara Pallotti25, Clara Malattia26 and Alberto Martini26, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Università degli Studi Milano-Bicocca, Milan, Italy, 3Cincinnati Children's Medical Center, Cincinnati, OH, 4National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, 5University of Minnesota, Minneapolis, MN, 6University of Utah, Salt Lake City, UT, 7Riley Hospital for Children at Indiana University, Indianapolis, IN, 8Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, 9Atrium Health Levine Children’s Hospital, Charlotte, NC, 10Cleveland Clinic, Cleveland, OH, 11Asklepios Klinik, Hamburg, Germany, 12Hôpital Necker-Enfants Malades, Paris, France, 13Department of Rheumatology and Clinical Immunology of Semmelweis University, Budapest, Hungary, 14Northwell, New Hyde Park, NY, 15Riga Stradiņš University, Riga, Latvia, 16Children’s Hospital of Georgia, Augusta University, Augusta, GA, 17IWK Grace Health Centre, Halifax, NS, Canada, 18University of Pittsburgh, Pittsburgh, PA, 19Randall Children’s Hospital at Legacy Emanuel, Portland, OR, 20McGill University Health Centre, Montreal, QC, Canada, 21Clinica de reumatología Guadalajara, Guadalajara, Jalisco, Mexico, 22Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, 23Bristol Myers Squibb, London, United Kingdom, 24Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 25Istituto G. Gaslini, Servizio di Sperimentazioni Cliniche Pediatriche, Genova, Italy, 26Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy

    Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients (pts) with JIA have been…
  • Abstract Number: 2626 • ACR Convergence 2025

    Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)

    Yusuf Yazici1 and Christopher Swearingen2, 1NYU Grossman School of Medicine, La Jolla, CA, 2Biosplice Therapeutics, Inc, San Diego, CA

    Background/Purpose: Increased pain and decreased function are hallmarks of knee OA progression. Lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways,…
  • Abstract Number: 2441 • ACR Convergence 2025

    Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial

    Zahi Touma1, Cynthia Aranow2, Ioannis Parodis3, Rosalind Ramsey-Goldman4, Matthias Schneider5, Christine de La Loge6, Teri Jimenez7, Mina Nejati8 and Laurent arnaud9, 1University of Toronto, Toronto, ON, Canada, 2Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, 3Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5Clinic of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Düsseldorf, Germany, 6UCB, Brussels, Belgium, 7UCB, Raleigh, NC, 8Biogen, Cambridge, MA, 9Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S 1109, Strasbourg, France, Strasbourg, France

    Background/Purpose: SLE imposes significant disease burden and diminishes health-related quality of life (HRQoL); improvement of HRQoL is therefore a key treatment goal in SLE.1,2 Dapirolizumab…
  • Abstract Number: 2289 • ACR Convergence 2025

    Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Disease Activity in Patients with Rheumatoid Arthritis: A Pilot Study

    Yuichiro Fujieda1, Kaoru Murakami2, Hiroki Tanaka2, Yuichi Kojima2, Yuki Kudo1, Kohei Karino1, Hiroyuki Nakamura1, Ryo Hisada1, Michihito Kono1, Masaaki Murakami2 and Tatsuya Atsumi1, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, 2Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    Background/Purpose: Vagus nerve stimulation (VNS) has emerged as a potential therapeutic strategy for inflammatory diseases by modulating inflammatory reflex pathways. Transcutaneous auricular vagus nerve stimulation…
  • Abstract Number: 1999 • ACR Convergence 2025

    Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials

    Herbert Baraf1, Andrew J. Sulich2, Guillermo J. Valenzuela3, Rehan Azeem4, Ben Peace5, Bhavisha Desai6 and Puja Khanna7, 1The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, 2Shores Rheumatology, St. Clair Shores, MI, 3Iris Rheumatology, Plantation, FL, 4Global MACD, Sobi Inc., Waltham, MA, 5Statistical Science, Sobi, Stockholm, Sweden, 6Sobi, Glastonbury, CT, 7Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Uricase-based therapies may profoundly lower serum uric acid (sUA) in patients (pts) with uncontrolled gout (UG) but often lead to anti-drug antibody (ADA) formation,…
  • Abstract Number: 1542 • ACR Convergence 2025

    Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-Week Phase 3 Trial

    Richard Furie1, George Bertsias2, Lucy Carter3, Eric Morand4, Marta Mosca5, Marilyn Pike6, Vanessa Taieb7, Annette Nelde8, Ed Vital9 and Christian Stach10, 1Division of Rheumatology, Northwell Health, Great Neck, NY, 2Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, 5University of Pisa, Pisa, Pisa, Italy, 6Rheumatology, MedPharm Consulting, Inc., Bethesda, MD, 7UCB, Colombes, France, 8Biogen, Baar, Switzerland, 9University of Leeds, Leeds, England, United Kingdom, 10UCB, Monheim am Rhein, Germany

    Background/Purpose: Despite the evolution of various flare definitions and their inclusion in SLE clinical trials, moderate flares tend to be underestimated in trials owing to…
  • Abstract Number: 1438 • ACR Convergence 2025

    Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension

    Félicie Costantino1, Ann-Sophie De Craemer2, Filip Van den Bosch2, Maxime Breban3, Vanessa Taieb4, Diana Voiniciuc5, Natasha de Peyrecave6, Dirk Elewaut7 and Maria-Antonietta D'Agostino8, 1Department of Rheumatology, Ambroise Paré Hospital, AP-HP, Paris, France and Infection & Inflammation, UMR 1173, Inserm, UVSQ/Université Paris Saclay, Montigny-Le-Bretonneux, France, 2Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 3CHU Ambroise-Paré, Boulogne-Billancourt, France, 4UCB, Colombes, France, 5UCB, Slough, United Kingdom, 6UCB, Brussels, Belgium, 7VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, 8Department of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

    Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease mainly affecting the sacroiliac joints and spine.1 Peripheral manifestations are common, contributing to disease burden.2 Two…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 55
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology